PharmaVoice

JULY 8, 2025

This slow and steady concept gained more validation in June when the company announced early but promising data from a phase 2 trial of its MEK inhibitor atebimetinib combined with chemotherapy, which showed a six-month 94% overall survival in pancreatic cancer.

Immunization 130

Immunization Chemotherapy Insurance Packaging 130

Pharmacy Times

JUNE 27, 2025

Mary Dzhuryan is a class of 2026 PharmD candidate at the USC Alfred E. Mehrnaz Razavi Vakhshoori is a class of 2026 PharmD candidate at the USC Alfred E. Because of its aggressive nature, MCL is typically treated with combination chemotherapy at diagnosis. Mann School of Pharmacy and Pharmaceutical Sciences in Los Angeles.

FDA 56

FDA Compounding Pharmacies Immunization Chemotherapy 56

Pharmaceutical Technology

JULY 1, 2025

Takeda anticipates commencing commercialisation efforts for Gammagard liquid ERC in the US by 2026, with plans to follow suit in the European Union (EU) by 2027. GlobalData Strategic Intelligence US Tariffs are shifting - will you react or anticipate? Don’t let policy changes catch you off guard. Sign up for our daily news round-up!

FDA 52

FDA Packaging Communication Hospitals 52

pharmaphorum

JUNE 8, 2022

Patients also have to undergo lymphodepleting chemotherapy to help prepare the body for the CAR-T cells. With Lunsumio, patients do not have to wait to start treatment and avoid the need for chemotherapy, which can sometimes not be an option at all for people who are frail.

Chemotherapy 105

Chemotherapy FDA 105

STAT

NOVEMBER 12, 2024

The medicine, Dato-DXd, is a type of next-generation chemotherapy called an antibody-drug conjugate that AstraZeneca and other companies are investing in heavily.   AstraZeneca had to resubmit a closely watched medicine for U.S.  Finally, AstraZeneca plans to invest $3.5 Continue to STAT+ to read the full story…

Chemotherapy 97

Chemotherapy Insurance 97

pharmaphorum

NOVEMBER 19, 2021

ORR in patients previously treated with chemotherapy. billion in 2026 sales for Retevmo and $723 million for Gavreto, although that was before Roche lent its marketing muscle to the Blueprint drug. The median duration of response still hasn’t been reached for the treatment-naïve group in the ongoing trial, with a 22.3

Chemotherapy 52

Chemotherapy 52

pharmaphorum

FEBRUARY 14, 2022

Padcev (enfortumab vedotin) is already approved as a second-line therapy for urothelial carcinoma (UC) after cisplatin chemotherapy and immunotherapy with checkpoint inhibitors, but Seagen and Astellas are working towards earlier use of the drug. billion-a-year product in 2026, according to GlobalData.

Chemotherapy 59

Chemotherapy FDA 59